{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=ViiV+Healthcare",
    "query": {
      "sponsor": "ViiV Healthcare",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 235,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=ViiV+Healthcare&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=ViiV+Healthcare&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T23:36:03.077Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02741557",
      "title": "Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DTG",
          "type": "DRUG"
        },
        {
          "name": "RPV",
          "type": "DRUG"
        },
        {
          "name": "DTG/RPV FDC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 118,
      "start_date": "2016-05-11",
      "completion_date": "2016-10-24",
      "has_results": false,
      "last_update_posted_date": "2019-07-15",
      "last_synced_at": "2026-10-11T23:36:03.077Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02741557"
    },
    {
      "nct_id": "NCT02720094",
      "title": "Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "TDF/FTC tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo for TDF/FTC tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo for cabotegravir oral tablet",
          "type": "DRUG"
        },
        {
          "name": "CAB LA",
          "type": "DRUG"
        },
        {
          "name": "Placebo for CAB LA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4570,
      "start_date": "2016-12-19",
      "completion_date": "2025-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-10-11T23:36:03.077Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02720094"
    },
    {
      "nct_id": "NCT06533280",
      "title": "VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Part A, C and D: VH3739937 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Part A: VH3739937 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Part A and C: Placebo",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment D",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment E",
          "type": "DRUG"
        },
        {
          "name": "Part D: Probe cocktail",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-08-02",
      "completion_date": "2024-08-14",
      "has_results": false,
      "last_update_posted_date": "2025-04-22",
      "last_synced_at": "2026-10-11T23:36:03.077Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06533280"
    },
    {
      "nct_id": "NCT00104429",
      "title": "GW873140 In Combination With Combivir In HIV Infected Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus I",
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "GW873140",
          "type": "DRUG"
        },
        {
          "name": "Combivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2005-01",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-10-11T23:36:03.077Z",
      "location_count": 27,
      "location_summary": "Bakersfield, California • Beverly Hills, California • Los Angeles, California + 21 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104429"
    },
    {
      "nct_id": "NCT05986084",
      "title": "Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pre-Exposure Prophylaxis (PrEP)",
        "Breast Feeding"
      ],
      "interventions": [
        {
          "name": "Cabotegravir Injection [Apretude]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 500,
      "start_date": "2023-11-30",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-11T23:36:03.077Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05986084"
    },
    {
      "nct_id": "NCT00102778",
      "title": "GW873140 In Combination With Kaletra In HIV Infected Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus I",
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "GW873140",
          "type": "DRUG"
        },
        {
          "name": "Kaletra (lopinavir/ritonavir)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2004-12",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-10-11T23:36:03.077Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00102778"
    },
    {
      "nct_id": "NCT04263142",
      "title": "A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK3640254 Tablet",
          "type": "DRUG"
        },
        {
          "name": "GSK3640254 Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 39,
      "start_date": "2020-01-27",
      "completion_date": "2020-03-24",
      "has_results": true,
      "last_update_posted_date": "2021-03-03",
      "last_synced_at": "2026-10-11T23:36:03.077Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04263142"
    },
    {
      "nct_id": "NCT02480894",
      "title": "A Open-label, Drug-Drug Interaction With Maraviroc (DDI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "BMS-663068",
          "type": "DRUG"
        },
        {
          "name": "Maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 112,
      "start_date": "2015-07-07",
      "completion_date": "2015-09-21",
      "has_results": false,
      "last_update_posted_date": "2017-09-25",
      "last_synced_at": "2026-10-11T23:36:03.077Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02480894"
    },
    {
      "nct_id": "NCT03784079",
      "title": "A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK3640254",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching GSK3640254 Mesylate salt",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 34,
      "start_date": "2019-01-31",
      "completion_date": "2020-02-06",
      "has_results": true,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-10-11T23:36:03.077Z",
      "location_count": 2,
      "location_summary": "Bakersfield, California • Orlando, Florida",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03784079"
    },
    {
      "nct_id": "NCT02185300",
      "title": "Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Dolutegravir Pediatric Granules",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir Dispersible Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2014-07",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2014-12-02",
      "last_synced_at": "2026-10-11T23:36:03.077Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02185300"
    }
  ]
}